Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel

International Journal of Oncology
Yi-Sheng ChouChien-Lin Liu

Abstract

Polo-like kinase 1 (PLK1), a serine/threonine kinase and an oncogene, is crucial in regulating cell cycle progression. PLK1 also has been demonstrated as a potential target of osteosarcoma (OS) by using short hairpin RNA libraries in lentiviral vectors for screening of protein kinase. In preclinical studies, GSK461364, a potent and selective ATP-competitive PLK1 inhibitor, showed antiproliferative activity against multiple tumor cell lines. In the present study, we evaluated the expression level of PLK1 in OS and explored the cytotoxic mechanism of GSK461364 against OS. PLK1 was significantly overexpressed in OS compared with normal osteoblasts and other types of sarcoma. GSK461364 inhibited PLK1 and caused mitotic arrest by inducing G2/M arrest in OS cells. Moreover, GSK461364 exerted a cytotoxic effect by inducing apoptosis in OS, and induced cellular senescence in OS cell lines, as indicated by an increased senescence-associated β-galactosidase activity and enhanced DcR2 and interleukin-1α expression. In addition, we demonstrated a synergistic cytotoxic effect of GSK461364 and paclitaxel, possibly resulting from combined mitotic arrest. In conclusion, the present study revealed that PLK1 was overexpressed in OS and that GSK4...Continue Reading

References

Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariUNKNOWN Italian and Scandinavian Sarcoma Groups
Mar 25, 2006·Nature Reviews. Cancer·Klaus Strebhardt, Axel Ullrich
Jun 2, 2007·The Lancet Oncology·Jay S WunderBenjamin A Alman
Dec 20, 2007·Journal of Pediatric Hematology/oncology·Nadezhda V KoshkinaErich M Sturgis
Aug 8, 2009·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Yukihide IwamotoShinya Yamawaki
Sep 4, 2009·Cancer Science·Umio YamaguchiTesshi Yamada
Sep 29, 2009·Journal of Cancer Research and Clinical Oncology·Matthew T HartingMartin L Blakely
Sep 23, 2010·Journal of the National Cancer Institute·Jonathan A EwaldDavid F Jarrard
Oct 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S WhelanH Gelderblom
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aimee M CragoSamuel Singer
Apr 12, 2014·Annals of Surgical Oncology·Giun-Yi HungHong-Jen Chiou
Dec 17, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A PerryKatherine A Janeway
Feb 14, 2015·Annals of Surgical Oncology·Min Wook JooYang-Guk Chung

❮ Previous
Next ❯

Citations

Mar 10, 2011·BMC Developmental Biology·Jyotika RajawatRasheedunnisa Begum
Aug 3, 2017·Cancer Medicine·Beverly A TeicherDavid Evans
Sep 6, 2019·International Journal of Oncology·Chueh-Chuan YenWei-Ming Chen
Aug 20, 2020·Cell Death and Differentiation·Yoon LimSharad Kumar
Sep 5, 2020·Journal of Drug Targeting·Ilma ShakeelMd Imtaiyaz Hassan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis